drugset / Trial / NCT06155084
A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients
Non-randomizedSequentialOpen-labelTreatment
Summary
The overall objective of this Phase 1 study is to evaluate the safety, PK,and anti-tumor activity of daily oral dosing with HP518,selecting the RP2D of HP518 based on assessments of patients with progressive mCRPC in dose-escalation phase
Timeline
- Start
- 2023-12-26
- Primary completion
- 2026-03
- Completion
- 2026-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HP518 | Unknown | 400 mg | Oral |
| Subject | HP518 | Unknown | 500 mg | Oral |